The world’s first saliva-based pregnancy tests developed by a Jerusalem-based startup will soon be on shelves in pharmacies and other retail stores in Israel, Europe, South Africa and the United Arab Emirates.

Salignotics, an Israeli biotech company that developed the pregnancy test based on technology used to make COVID-19 testing kits, said on Wednesday that the SaliStick test kits will be available in these regions early next year. The company said it is in advanced discussions with distributors to deliver the kits in the first quarter of 2023.

The Israeli company, founded in 2016, received European CE certification for SaliStick to be marketed in the European Union as well as approval from the Israeli Ministry of Health. Salignostics is currently in the process of seeking FDA approval in the US.

Last year, the company said it successfully completed clinical trials in Israel on more than 300 women — both pregnant and non-pregnant — and was hoping to soon commercialize the kits. It has since set up a manufacturing facility in the Lavon industrial park in the Galilee in northern Israel with a monthly production capacity of a million units, the company said.

“It is deeply encouraging that technology that was honed and developed to help us deal with one of the worst pandemics is able to be developed further to help contribute to help and wellness for women and families all over the world,” Dr. Guy Krief, co-founder and deputy CEO at Salignostics, told The Times of Israel at the time.

The saliva test is as simple (and likely less messy) as traditional pregnancy tests, minus having to aim all the urine. People taking the test insert one part of the test kit into their mouth for several seconds to collect saliva and into a testing tube, which delivers results in under 10 minutes, according to the company. Like many urine-based tests, Salignostics’ saliva test can be taken on the first day of a missed period to detect the presence of the pregnancy hormone β-hCG (Human Chorionic Gonadotropin).

A result of two lines likely indicates a pregnancy.

With the test, Salignotics is marking its entry into a global pregnancy testing market that is expected to be valued at nearly $2 billion by 2030.

The Israeli company was founded by a team of researchers at the Hebrew University of Jerusalem who have focused on saliva as a key diagnostics indicator.

In addition to Salignostics’s SaliStick and COVID-19 tests, which have sold widely in Europe and Africa, the company also sells diagnostic kits for the detection of malaria cardiac risk, and an intestinal bacterial infection called Helicobacter pylori, among others.

“Saliva is the key to rapid diagnostics for a variety of medical reasons. It is the only non-invasive, easy and hygienic means to detect hormones, viruses and even diseases,” said Professor Aaron Palmon, co-founder of Salignostics, in a statement on Wednesday.

“With SaliStick, we leverage the powerful diagnostics abilities we have been able to create from analyzing saliva. This product completely removes the need for blood and urine samples when testing for pregnancy,” he said.

During the development of the SaliStick tests, the company raised some $16 million in capital from private investors and received four grants from the Israel Innovation Authority. Salignostics said it was now raising additional capital to support sales, marketing and R&D operations.

I joined The Times of Israel after many years covering US and Israeli politics for Israeli news outlets.

I believe responsible coverage of Israeli politicians means presenting a 360 degree view of their words and deeds – not only conveying what occurs, but also what that means in the broader context of Israeli society and the region.

That’s hard to do because you can rarely take politicians at face value – you must go the extra mile to present full context and try to overcome your own biases.

I’m proud of our work that tells the story of Israeli politics straight and comprehensively. I believe Israel is stronger and more democratic when professional journalists do that tough job well.

Your support for our work by joining The Times of Israel Community helps ensure we can continue to do so.

Thank you,
Tal Schneider, Political Correspondent

We’re really pleased that you’ve read X Times of Israel articles in the past month.

That’s why we started the Times of Israel ten years ago - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.

So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.

For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.

Thank you,
David Horovitz, Founding Editor of The Times of Israel

QOSHE - World’s 1st saliva pregnancy test by Israeli startup to hit shelves next year - Ricky Ben-David
We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

World’s 1st saliva pregnancy test by Israeli startup to hit shelves next year

16 0 0
09.11.2022

The world’s first saliva-based pregnancy tests developed by a Jerusalem-based startup will soon be on shelves in pharmacies and other retail stores in Israel, Europe, South Africa and the United Arab Emirates.

Salignotics, an Israeli biotech company that developed the pregnancy test based on technology used to make COVID-19 testing kits, said on Wednesday that the SaliStick test kits will be available in these regions early next year. The company said it is in advanced discussions with distributors to deliver the kits in the first quarter of 2023.

The Israeli company, founded in 2016, received European CE certification for SaliStick to be marketed in the European Union as well as approval from the Israeli Ministry of Health. Salignostics is currently in the process of seeking FDA approval in the US.

Last year, the company said it successfully completed clinical trials in Israel on more than 300 women — both pregnant and non-pregnant — and was hoping to soon commercialize the kits. It has since set up a manufacturing facility in the Lavon industrial park in the Galilee in northern Israel with a monthly production capacity of a million units, the company said.

“It is deeply encouraging that technology that was honed and developed to help us deal with one of the worst........

© The Times of Israel


Get it on Google Play